The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
According to AbbVie's latest financial reports the company's current revenue (TTM ) is NZ$92.20 Billion. In 2023 the company made a revenue of NZ$85.89 Billion a decrease over the revenue in the year 2022 that were of NZ$91.43 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.